HK Stock Market Move | XUANZHUBIO-B (02575) rose more than 9% in the final trading session to hit a new market high. NG-350A was previously granted expedited qualification by the US FDA.

XUANZHUBIO-B (02575) rose more than 9% at the close, hitting a high of 71.6 Hong Kong dollars, marking a new high in the stock market. As of the time of writing, it has risen by 6.41% to 69.7 Hong Kong dollars, with a trading volume of 38.59 million Hong Kong dollars. On the news front, Xuanzhu Biotechnology announced at the end of last month that the product NG-350A, licensed from the clinical-stage oncology company Akamis, has been granted Fast Track designation by the Food and Drug Administration (FDA) of the United States for the treatment of locally advanced rectal cancer with intact mismatch repair function. The group has exclusive rights for the development, production, and commercialization of the NG-350A product in Greater China. It is worth noting that from October 30 to November 3, the National Medical Insurance Administration organized negotiations and bidding for the 2025 National Basic Medical Insurance Drug Catalogue and price negotiations for innovative drugs in commercial insurance. The list of preliminary examination results published by the National Medical Insurance Administration showed that Xuanzhu Biotechnology's Piroxicam tablets have successfully entered the list. For Piroxicam tablets, whether they can ultimately be included in the National Medical Insurance Catalogue is also crucial.